Reply to Olschewski <i>et al.</i>: TMEM16A Potentiation: Possible Drawbacks.

Danahay, Henry L; Morris, David G; Gosling, Martin

Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks.

Danahay, Henry L; Morris, David G; Gosling, Martin.

Danahay HL; Enterprise Therapeutics Brighton, United Kingdom and.
Morris DG; Enterprise Therapeutics Brighton, United Kingdom and.
Gosling M; Enterprise Therapeutics Brighton, United Kingdom and.

Am J Respir Crit Care Med ; 202(6): 905-906, 2020 09 15.

Article en En | MEDLINE | ID: mdl-32464067

Asunto(s)

Fibrosis Quística; Humanos; Proteínas de Neoplasias

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491402
https://dx.doi.org/10.1164/rccm.202004-1214LE

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrosis Quística Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491402
https://dx.doi.org/10.1164/rccm.202004-1214LE

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrosis Quística Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article